Cagrilintide news

All news on Cagrilintide (also known as AM833): plants, production capacities, investments and involved companies.

28 April 2026

Novo Nordisk to present Wegovy and next‑generation obesity data at ECO 2026

Presenting 52 abstracts at ECO: data on semaglutide (injectable and oral), higher‑dose 7.2 mg, CagriSema combo, menopause effects, CV risk, weight‑loss timelines and real‑world outcomes.
23 February 2026

Novo Nordisk: CagriSema Shows 23% Weight Loss in Trial, Misses Primary Endpoint

CagriSema achieved 23% weight loss in 84 weeks but didn't match tirzepatide. Further trials will explore higher doses. Safe profile with mild gastrointestinal effects.
2 February 2026

Novo Nordisk Announces REIMAGINE 2 Trial Results

CagriSema showed superior HbA1c reduction and weight loss over semaglutide in a 68-week trial with type 2 diabetes patients inadequately controlled with metformin.
18 December 2025

Novo Nordisk Seeks FDA Approval for CagriSema, a Weekly Obesity Treatment

CagriSema, combining cagrilintide and semaglutide, shows 23% weight loss in trials. If approved, it offers a new obesity treatment option.
18 December 2025

Novo Nordisk Seeks FDA Approval for CagriSema, a Weekly Obesity Treatment

CagriSema, a weekly injectable combining GLP-1 and amylin analogues, shows promising weight loss results in trials and awaits FDA review for obesity management.
6 November 2025

Novo Nordisk's CagriSema Reduces Blood Pressure and Inflammation, Lowers Heart Disease Risk

CagriSema shows potential in reducing blood pressure, inflammation, and heart disease risk, with ongoing trials to assess cardiovascular outcomes.

Who will be producing Cagrilintide in the future?

Find out with chemXplore Alpha

Learn more